Ryott Michael, Wangsa Darawalee, Heselmeyer-Haddad Kerstin, Lindholm Johan, Elmberger Göran, Auer Gert, Avall Lundqvist Elisabeth, Ried Thomas, Munck-Wikland Eva
Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Karolinska University Hospital, Stockholm S-17176, Sweden.
Eur J Cancer. 2009 Jun;45(9):1700-8. doi: 10.1016/j.ejca.2009.02.027. Epub 2009 Mar 28.
New promising therapeutic agents targeting epidermal growth factor receptor (EGFR) have been developed although clinical information concerning EGFR status in oral tongue squamous cell carcinoma (OTSCC) is limited. We investigated EGFR protein expression and gene copy numbers in 78 pretreatment OTSCC paraffin samples. EGFR protein expression was found in all 78 tumours, of which 72% showed an intense staining. Fifty-four percent of the tumours had high (> or =four gene copies) EGFR gene copy numbers. EGFR gene copy number was significantly associated with EGFR protein expression (P=0.002). Pretreatment EGFR staining intensity tended to be associated with non-pathological complete remission after preoperative radiotherapy for Stage II OTSCC. No correlation was found between EGFR status and survival. EGFR FISH results were significantly (P=0.003) higher in more advanced tumours (Stages II, III and IV) than in the tumours in Stage I. Non-smokers exhibited a significantly higher EGFR gene copy number and protein overexpression in Stages I and II OTSCC than smokers (P=0.001, P=0.009). In conclusion, EGFR was found to be overexpressed in all OTSCCs making this cancer type interesting for exploring new therapeutic agents targeting the EGFR receptor.
尽管关于口腔舌鳞状细胞癌(OTSCC)中表皮生长因子受体(EGFR)状态的临床信息有限,但针对EGFR的新型有前景的治疗药物已被开发出来。我们研究了78例OTSCC预处理石蜡样本中的EGFR蛋白表达和基因拷贝数。在所有78个肿瘤中均发现了EGFR蛋白表达,其中72%表现为强染色。54%的肿瘤具有高(≥4个基因拷贝)EGFR基因拷贝数。EGFR基因拷贝数与EGFR蛋白表达显著相关(P = 0.002)。对于II期OTSCC,预处理时EGFR染色强度倾向于与术前放疗后的非病理完全缓解相关。未发现EGFR状态与生存率之间存在相关性。在更晚期的肿瘤(II、III和IV期)中,EGFR荧光原位杂交(FISH)结果显著高于I期肿瘤(P = 0.003)。在I期和II期OTSCC中,非吸烟者的EGFR基因拷贝数和蛋白过表达显著高于吸烟者(P = 0.001,P = 0.009)。总之,发现EGFR在所有OTSCC中均过度表达,这使得这种癌症类型对于探索针对EGFR受体的新型治疗药物具有吸引力。